Targeting JNK for therapeutic benefit: from junk to gold?

By Anthony M. Manning, R. Davis. Nature reviews. Drug discovery, 2003

621 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/e424d926257ac9804df004f80fb1390618543de6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. C. Der
2. P. Roberts

In Oncology

1. C. Der
2. P. Roberts

In Pathology and Forensic Medicine

1. C. Der
2. P. Roberts

Citations in the corpus

• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “In contrast to p38 inhibitors, only a handful of JNK inhibitors have been developed, and are being considered for the treatment of cancer, as well as inflammatory , vascular, neurodegenerative and metabolic disorders (Manning and Davis, 2003).”